Of the drug’s $608 list price, Ms. Bresch claims Canonsburg, Pa.-based Mylan only receives $274 per two-pack sold, or 45 percent. She says the remaining $334, or 55 percent, goes to pharmacy benefit managers, insurers, wholesalers and pharmacy retailers.
Ms. Bresch believes that when Mylan raises the price of a drug, it is not the drugmaker but these middlemen who are to blame for high drug costs, since they consequently raise the price patients must pay for the treatment through insurance premiums or at the pharmacy counter, according to the report.
She highlights the inefficiency of the drug industry’s current distribution system and said that “congress and other leaders of this country need to quit putting their toe in this topic and really fix this system,” the report states.
More articles on supply chain:
New York attorney general investigates Mylan over potential antitrust violations in school contracts
Weighing the cost of care: How hospitals accommodate obese patients
Is Mylan really the bad guy? 4 thoughts from a leading healthcare strategist on the big picture of pharma price hikes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
